Literature DB >> 20842339

[Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

A Schneider1, P Falkai, A Papassotiropoulos.   

Abstract

Neurofibrillary tangles are the hallmark of Alzheimer's disease together with amyloid plaques. They are composed of hyperphosphorylated and aggregated Tau proteins. Consequently, experimental disease modifying approaches include kinase and aggregation inhibitors as well as substances which increase degradation of Tau proteins.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20842339     DOI： 10.1007/s00115-010-3052-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  51 in total

1.  Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments.

Authors:  Félix Hernández; José Borrell; Carmen Guaza; Jesús Avila; José J Lucas
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

2.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.

Authors:  Bin Zhang; Arpita Maiti; Sharon Shively; Fara Lakhani; Gaye McDonald-Jones; Jennifer Bruce; Edward B Lee; Sharon X Xie; Sonali Joyce; Chi Li; Philip M Toleikis; Virginia M-Y Lee; John Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

Review 3.  Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

4.  Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish.

Authors:  Frauke van Bebber; Dominik Paquet; Alexander Hruscha; Bettina Schmid; Christian Haass
Journal:  Neurobiol Dis       Date:  2010-04-08       Impact factor: 5.996

5.  Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease.

Authors:  B Hempen; J P Brion
Journal:  J Neuropathol Exp Neurol       Date:  1996-09       Impact factor: 3.685

6.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

7.  A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.

Authors:  Yasuji Matsuoka; Yan Jouroukhin; Audrey J Gray; Li Ma; Chiho Hirata-Fukae; Hui-Fang Li; Li Feng; Laurent Lecanu; Benjamin R Walker; Emmanuel Planel; Ottavio Arancio; Illana Gozes; Paul S Aisen
Journal:  J Pharmacol Exp Ther       Date:  2008-01-16       Impact factor: 4.030

Review 8.  Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.

Authors:  Kurt R Brunden; Carlo Ballatore; Alex Crowe; Amos B Smith; Virginia M-Y Lee; John Q Trojanowski
Journal:  Exp Neurol       Date:  2009-09-08       Impact factor: 5.330

9.  Lithium induces autophagy by inhibiting inositol monophosphatase.

Authors:  Sovan Sarkar; R Andres Floto; Zdenek Berger; Sara Imarisio; Axelle Cordenier; Matthieu Pasco; Lynnette J Cook; David C Rubinsztein
Journal:  J Cell Biol       Date:  2005-09-26       Impact factor: 10.539

10.  Transmission and spreading of tauopathy in transgenic mouse brain.

Authors:  Florence Clavaguera; Tristan Bolmont; R Anthony Crowther; Dorothee Abramowski; Stephan Frank; Alphonse Probst; Graham Fraser; Anna K Stalder; Martin Beibel; Matthias Staufenbiel; Mathias Jucker; Michel Goedert; Markus Tolnay
Journal:  Nat Cell Biol       Date:  2009-06-07       Impact factor: 28.824
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.